Skip to main content
Premium Trial:

Request an Annual Quote

Cell Genesys, Lentigen, Promega

Premium
Cell Genesys Sells Lentiviral Delivery Technology to Lentigen
 
Cell Genesys announced last month that it has sold its lentiviral gene-delivery technology to GBP Capital, the majority shareholder of gene delivery firm Lentigen, for $12 million.
 
The deal covers all intellectual property related to the lentiviral vector technology, as well as existing licensing arrangements. Cell Genesys will retain rights to the technology for research and development purposes.
 
Management of technology and IP, the companies said, has been assigned to Lentigen by GBP.
 
Additional terms of the arrangement were not disclosed.
 

 
Promega to Open Office in Sweden This Month
 
Promega said late last month that it will open an office in Stockholm in January to offer its products and services directly to the Swedish research community.
 
The company, based in Madison, Wis., previously offered its products in Sweden through a distribution deal with SDS BioSciences.  
 
The company has hired Patrick Van de Velde as general manager of the office.
 
In a statement, Promega CEO William Linton said that Sweden has the fourth-largest biotech industry in Europe with 48,000 full-time employees in R&D and the highest R&D expenditure per capita.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.